Health Nih Articles & Analysis
173 news found
According to the National Institutes of Health (NIH), there are over 7,000 known rare diseases, impacting an estimated 300 million people globally. ...
DOE will co-lead NAIRR Secure alongside the National Institutes of Health (NIH) to enable AI research requiring privacy and security-preserving resources and will assemble exemplar privacy preserving resources. ...
BIOtechNOW featured IVS’s participating BIO Innovation Zone Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. ...
How has the NIH SBIR program helped you in working to achieveyour long-term goals? National Institute of Health (NIH) SBIR program has supported IVS to achieve proof-of-concept studies of drug discovery applications of our innovative technologies in collaboration with major pharmaceutical companies. NIH’s leadership has ...
“ This clinical trial was sponsored by the National Institutes of Health’s (NIH) National Center for Complementary and Integrative Health (NCCIH).* Further information can be found at ...
“We have been working closely with FDA and our funder, the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to finalize our protocol for our first-in-human study, and we look forward to initiating our Phase 1a study of OLX-07010 in the coming ...
HHSN272201800001I/75N93023F00001) held by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). The first study met its objectives and generated positive data as announced in February 2022. ...
” Earlier this year, VeriSIM was awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to fund the AI-driven development of medications for substance use disorder (SUD). ...
Immune-Onc has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and a strategic investment from The Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP). ...
It has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). ...
Guy Ellis, Chief Operating Officer of Anavasi Diagnostics, brings extensive healthcare and high-tech industry experience – particularly in companies that excelled in growing and transforming technology, global health, laboratories, professional services, and intellectual property. His work in a healthcare non-profit (Global Health Labs), an investment firm ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
Immune-Onc has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and a strategic investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions and community based health emergencies, announced today that the U.S. Food and Drug Administration (FDA) has granted its lead compound, ENA-001, Orphan Drug Designation for the treatment of Apnea of Prematurity (AoP). ...
The first phase of the contract, which provides approximately $6 million to complete activities through the initial phase 1 study, coincides with grant support from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. The new award builds on an existing partnership between Enalare Therapeutics and the BARDA DRIVe ReDIRECT (Repurposing Drugs in ...
Immune-Onc has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and a strategic investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). ...
The study, conducted with the support of Emory and Georgia Tech University, was sponsored by a grant from the National Institute on Drug Addiction (NIDA), part of the National Institutes of Health (NIH), through NIH Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative. ...
The National Institutes of Health (NIH) has awarded Berkshire Biomedical Awarded $266,000 to support continued development of an automated, at-home methadone administration system. ...
(Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the National Institute on Drug Abuse, part of the National Institutes of Health (NIH), has awarded Columbia University a multi-year NIDA grant to fund clinical ...
To learn more about this EB study, view the detailed study description on the National Institutes of Health (NIH) clinicaltrials.gov website. Learn more about InMed’s INM-755 EB study: https://www.inmedpharma.com/pharmaceutical/inm-755-for-epidermolysis-bullosa/ What is epidermolysis bullosa? ...